Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) reported that its RAD101 imaging agent met the primary endpoint of a Phase 2b ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE